Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica

  1. M.Á. Royo-Bordonada 1
  2. P. Armario 2
  3. J.M. Lobos Bejarano 3
  4. J. Pedro-Botet 4
  5. F. Villar Alvarez 4
  6. R. Elosua 5
  7. C. Brotons Cuixart 3
  8. O. Cortés 6
  9. B. Serrano 7
  10. M. Cammafort Babkowski 8
  11. A. Gil Núñez 9
  12. A. Pérez 10
  13. A. Maiques 3
  14. A. de Santiago Nocito 11
  15. A. Castro 12
  16. E. Alegría 12
  17. C. Baeza 13
  18. M. Herranz 14
  19. S. Sans 15
  20. P. Campos 16
  1. 1 Instituto de Salud Carlos III, España
  2. 2 Sociedad Española de Hipertensión-Liga Española de la Lucha Contra la HTA, España
  3. 3 Sociedad Española de Medicina de Familia y Comunitaria, España
  4. 4 Sociedad Española de Arteriosclerosis, España
  5. 5 Sociedad Española de Epidemiología, España
  6. 6 Asociación Española de Pediatría de Atención Primaria, España
  7. 7 Sociedad Española de Medicina y Seguridad en el Trabajo, España
  8. 8 Sociedad Española de Medicina Interna, España
  9. 9 Sociedad Española de Neurología, España
  10. 10 Sociedad Española de Diabetes, España
  11. 11 Sociedad Española de Médicos de Atención Primaria-Semergen, España
  12. 12 Sociedad Española de Cardiología, España
  13. 13 Sociedad Española de Angiología y Cirugía Vascular, España
  14. 14 Federación de Asociaciones de Enfermería Comunitaria y Atención Primaria, España
  15. 15 Sociedad Española de Salud Pública y Administración Sanitaria, España
  16. 16 Ministerio de Sanidad, Servicios Sociales e Igualdad, España
Show affiliations +
Journal:
Hipertensión y riesgo vascular

ISSN: 1889-1837

Year of publication: 2017

Volume: 34

Issue: 1

Pages: 24-40

Type: Article

DOI: 10.1016/J.HIPERT.2016.11.006 DIALNET GOOGLE SCHOLAR

More publications in: Hipertensión y riesgo vascular

Abstract

The VI European Guidelines for Cardiovascular Prevention recommend combining population and high-risk strategies with lifestyle changes as a cornerstone of prevention, and propose the SCORE function to quantify cardiovascular risk. The guidelines highlight disease specific interventions, and conditions as women, young people and ethnic minorities. Screening for subclinical atherosclerosis with noninvasive imaging techniques is not recommended. The guidelines distinguish four risk levels (very high, high, moderate and low) with therapeutic objectives for lipid control according to risk. Diabetes mellitus confers a high risk, except for subjects with type 2 diabetes with less than <10 years of evolution, without other risk factors or complications, or type 1 diabetes of short evolution without complications. The decision to start pharmacological treatment of arterial hypertension will depend on the blood pressure level and the cardiovascular risk, taking into account the lesion of target organs. The guidelines don’t recommend antiplatelet drugs in primary prevention because of the increased bleeding risk. The low adherence to the medication requires simplified therapeutic regimes and to identify and combat its causes. The guidelines highlight the responsibility of health professionals to take an active role in advocating evidence-based interventions at the population level, and propose effective interventions, at individual and population level, to promote a healthy diet, the practice of physical activity, the cessation of smoking and the protection against alcohol abuse.

Data source: Dialnet